128811-48-3

Basic information

• Product Name: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE
• Synonyms: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE;(R)-5-OXO-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER 2-METHYL ESTER;METHYL (R)-N-(TERT-BUTOXYCARBONYL)PYROGLUTAMATE;Boc-D-Pyroglutamic acid methyl ester;Boc-L-pyroglutamic acid methyl ester;(R)-1-Tert-butyl2-Methyl5-oxopyrrolidine-1,2-dicarboxylate;(R)-N-(tert-butoxycarbonyl)pyroglutaMate;1-Boc-5-oxo-D-proline Methyl ester
• CAS NO: 128811-48-3
• Molecular Formula: C₁₁H₁₇NO₅
• Molecular Weight: 243.26
• Mol File: 128811-48-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 68-69℃
• Boiling Point: 361.637 °C at 760 mmHg
• Flash Point: 172.512 °C
• Appearance: /
• Density: 1.209
• Refractive Index: 1.506
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -4.28±0.40(Predicted)
• CAS DataBase Reference: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE(128811-48-3)
• EPA Substance Registry System: (R)-N-BOC-5-METHOXYCARBONYL-2-PYRROLIDINONE(128811-48-3)

Safety Data

• Hazardous Substances Data: 128811-48-3(Hazardous Substances Data)

Usage

Uses

(R)-1-tert-Butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate is a useful intermediate used in the synthesis of (-)-Kaitocephalin; a non-selective ionotropic glutamate receptor antagonist.

InChI:InChI=1/C11H17NO5/c1-10(2,3)17-9(16)12-7(13)5-6-11(12,4)8(14)15/h5-6H2,1-4H3,(H,14,15)/t11-/m1/s1

Upstream product

• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 68766-96-1 ethyl (R)-2-pyrrolidone-5-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 130621-90-8 (S)-4-(Hydroxy-phenyl-methyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 144978-32-5 (Z)-(R)-2-tert-Butoxycarbonylamino-7-hydroxy-5-oxo-7-phenyl-hept-6-enoic acid ethyl ester 
• 400626-55-3 (2R,4S)-5-Oxo-4-[4-(3-phenyl-ureido)-benzyl]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-53-1 (2R,4S)-4-(4-Benzenesulfonylamino-benzyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-43-9 (2R,4S)-4-(4-Naphthalen-2-yl-benzyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-37-1 4-(3-benzo[b]thiophen-2-yl-benzyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-44-0 4-(4-benzo[b]thiophen-2-yl-benzyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-41-7 (2R,4S)-5-Oxo-4-(4-thiophen-3-yl-benzyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-62-2 (2R,4S)-4-(3-Furan-2-yl-benzyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 400626-33-7 (2R,4R)-4-(Benzoylamino-methyl)-5-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 

Relevant articles and documents

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP4 subtype of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP 4 sub type of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and theiruse as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.